Conflict of Interest Disclosures: Dr Tidblad reported personal fees from Pfizer outside the submitted work. Dr Sävendahl reported grants from Regional University Hospital grants paid to Karolinska University Hospital and the Swedish Research Council paid to Karolinska Institutet during the conduct of the study; personal fees from Ascendis Honorarium, Hexal Lecture, Merck Lecture, Novo Nordisk Honorarium, Pfizer, and Sandoz Honorarium outside the submitted work. No other disclosures were reported.


CORRECTION

Error in the Text: In the Original Investigation titled “A Budget Impact Analysis of Gene Therapy for Sickle Cell Disease: The Medicaid Perspective,” which published online March 22, 2021,1 there was an error in the Introduction section. The third sentence in the fourth paragraph of that section should read: “A gene therapy using the same lentiviral vector received conditional approval from the European Medicines Agency in 2019 for the treatment of transfusion-dependent β-thalassemia.” This article was corrected online.